Detalhe da pesquisa
1.
Pharmacokinetics and safety of LEAD-452, an EGFR-specific 4-1BB-agonistic trimerbody in non-human primates.
Toxicol Appl Pharmacol;
487: 116961, 2024 May 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38740095
2.
A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response.
Oncoimmunology;
12(1): 2205336, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37114242
3.
Dendritic Cell-Mediated Cross-Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS-CoV-2.
Adv Sci (Weinh);
10(34): e2304818, 2023 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37863812
4.
Tumor targeted 4-1BB agonist antibody-albumin fusions with high affinity to FcRn induce anti-tumor immunity without toxicity.
iScience;
25(9): 104958, 2022 Sep 16.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36072551
5.
Der p 1-based immunotoxin as potential tool for the treatment of dust mite respiratory allergy.
Sci Rep;
10(1): 12255, 2020 07 23.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32703972
6.
Inclusion of a Furin Cleavage Site Enhances Antitumor Efficacy against Colorectal Cancer Cells of Ribotoxin α-Sarcin- or RNase T1-Based Immunotoxins.
Toxins (Basel);
11(10)2019 10 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31614771
7.
Fungal Ribotoxins: A Review of Potential Biotechnological Applications.
Toxins (Basel);
9(2)2017 02 21.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28230789